Evommune (NYSE:EVMN) Shares Gap Up – Should You Buy?

Evommune, Inc. (NYSE:EVMN) shares gapped up before the market opened on Thursday . The stock had previously closed at $16.20, but opened at $17.13. Evommune shares last traded at $18.04, with a volume of 106,582 shares.

Key Evommune News

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: HC Wainwright initiated coverage on Evommune with a “Buy” rating and a $35 price target, citing expectations for improving results — this analyst endorsement and target well above the recent trading level is likely supporting upside in the stock. Evommune (NYSE:EVMN) Research Coverage Started at HC Wainwright
• Positive Sentiment: HC Wainwright provided updated EPS forecasts showing a materially smaller full‑year loss in FY2026 (‑$1.40) versus FY2025 (‑$4.36), signaling an expected financial improvement trajectory that can boost investor sentiment. HC Wainwright Estimates on MarketBeat
• Neutral Sentiment: HC Wainwright also published quarter‑by‑quarter EPS estimates for 2025–2026 (Q1–Q4 2026 roughly ‑$0.34 to ‑$0.36 per quarter), which confirm continued near‑term losses even as the firm models improvement — useful for gauging the pace of recovery but still indicative of ongoing cash burn and execution risk. HC Wainwright Estimates on MarketBeat

Analysts Set New Price Targets

A number of equities research analysts have weighed in on EVMN shares. Leerink Partners started coverage on Evommune in a report on Monday, December 1st. They set an “outperform” rating and a $42.00 price objective on the stock. Leerink Partnrs raised Evommune to a “strong-buy” rating in a research note on Monday, December 1st. William Blair initiated coverage on Evommune in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. Zacks Research raised Evommune to a “hold” rating in a report on Tuesday, December 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Evommune in a report on Monday, December 1st. They issued an “overweight” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $38.60.

Evommune Price Performance

The firm has a market cap of $640.49 million and a price-to-earnings ratio of -2.52.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, December 11th. The company reported ($8.07) EPS for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.00 million.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.